Literature DB >> 26797355

Differentiating Mass-Forming Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma on the Basis of Contrast-Enhanced MRI and DWI Findings.

Seo-Youn Choi1, Seong Hyun Kim2, Tae Wook Kang2, Kyoung Doo Song2, Hyun Jeong Park3, Yoon-Hyeong Choi4.   

Abstract

OBJECTIVE: The purpose of this study was to assess value of contrast-enhanced MRI, MRCP, and DWI for differentiating mass-forming autoimmune pancreatitis (AIP) from pancreatic ductal adenocarcinoma (PDAC).
MATERIALS AND METHODS: This study included 15 patients with mass-forming AIP and 79 with PDAC who underwent gadoxetic acid-enhanced MRI with DWI and MRCP. Two radiologists evaluated the MRI findings in consensus. Statistically significant imaging findings were identified through univariate and multivariate analyses, and their diagnostic performance for predicting mass-forming AIP was analyzed.
RESULTS: In the univariate analysis, multiplicity, similar or high signal intensity on portal phase and 3- and 20-minute delayed phase images, homogeneous enhancement, no peripancreatic fat infiltration, no internal cystic or necrotic portion, capsulelike rim, no upstream pancreatitis, no vascular invasion, and duct penetrating sign were more frequently observed (p < 0.05) in mass-forming AIP. The apparent diffusion coefficient (ADC) value was also significantly lower for mass-forming AIP than for PDAC (0.96 ± 0.14 versus 1.13 ± 0.23 × 10(-3) mm(2)/s; p < 0.001). The optimal cutoff value of ADC for differentiating mass-forming AIP from PDAC was 0.9407 × 10(-3) mm(2)/s. In multivariate analysis, homogeneous enhancement (p = 0.001), duct penetrating sign (p < 0.001), and ADC value less than 0.9407 × 10(-3) mm(2)/s (p < 0.001) were significant for differentiating mass-forming AIP from PDAC. When two of these three criteria were combined, 80% (12/15) of mass-forming AIPs were identified with specificity of 98.7%. When all three criteria were satisfied, specificity was 100%.
CONCLUSION: Contrast-enhanced MRI with MRCP and DWI may be helpful for differentiating mass-forming AIP from PDAC.

Entities:  

Keywords:  DWI; MRCP; apparent diffusion coefficient; autoimmune pancreatitis; pancreatic ductal adenocarcinoma

Mesh:

Substances:

Year:  2016        PMID: 26797355     DOI: 10.2214/AJR.15.14974

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  19 in total

1.  Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma.

Authors:  Sunyoung Lee; Jin Hee Kim; So Yeon Kim; Jae Ho Byun; Hyoung Jung Kim; Myung-Hwan Kim; Moon-Gyu Lee; Seung Soo Lee
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

2.  European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations.

Authors:  J-Matthias Löhr; Ulrich Beuers; Miroslav Vujasinovic; Domenico Alvaro; Jens Brøndum Frøkjær; Frank Buttgereit; Gabriele Capurso; Emma L Culver; Enrique de-Madaria; Emanuel Della-Torre; Sönke Detlefsen; Enrique Dominguez-Muñoz; Piotr Czubkowski; Nils Ewald; Luca Frulloni; Natalya Gubergrits; Deniz Guney Duman; Thilo Hackert; Julio Iglesias-Garcia; Nikolaos Kartalis; Andrea Laghi; Frank Lammert; Fredrik Lindgren; Alexey Okhlobystin; Grzegorz Oracz; Andrea Parniczky; Raffaella Maria Pozzi Mucelli; Vinciane Rebours; Jonas Rosendahl; Nicolas Schleinitz; Alexander Schneider; Eric Fh van Bommel; Caroline Sophie Verbeke; Marie Pierre Vullierme; Heiko Witt
Journal:  United European Gastroenterol J       Date:  2020-06-18       Impact factor: 4.623

3.  The role of apparent diffusion coefficient value in the diagnosis of localized type 1 autoimmune pancreatitis: differentiation from pancreatic ductal adenocarcinoma and evaluation of response to steroids.

Authors:  Tsuyoshi Sekito; Yasutaka Ishii; Masahiro Serikawa; Tomofumi Tsuboi; Ryota Kawamura; Ken Tsushima; Shinya Nakamura; Tetsuro Hirano; Ayami Fukiage; Takeshi Mori; Juri Ikemoto; Yusuke Kiyoshita; Sho Saeki; Yosuke Tamura; Sayaka Miyamoto; Kazuaki Chayama
Journal:  Abdom Radiol (NY)       Date:  2021-01-01

Review 4.  Accuracy of quantitative diffusion-weighted imaging for differentiating benign and malignant pancreatic lesions: a systematic review and meta-analysis.

Authors:  LuShun Zhang; LongLin Yin; MeiLin Zhu; ChuanDe Zhang; JingXin Yan; Ju Sun; XinYi Zhao
Journal:  Eur Radiol       Date:  2021-04-13       Impact factor: 5.315

Review 5.  Follicular pancreatitis: A rare pancreatic inflammatory pseudotumor.

Authors:  W James Tom; Xiangdong Xu; Noushin Vahdat; Fiona Cassidy; Lejla Aganovic
Journal:  Clin Imaging       Date:  2019-10-25       Impact factor: 1.605

Review 6.  Autoimmune Pancreatitis.

Authors:  Binit Sureka; Archana Rastogi
Journal:  Pol J Radiol       Date:  2017-02-25

7.  Multi-modality imaging features distinguish pancreatic carcinoma from mass-forming chronic pancreatitis of the pancreatic head.

Authors:  Zhibing Ruan; Jun Jiao; Dingyu Min; Jinhuan Qu; Jing Li; Jing Chen; Qi Li; Chunhong Wang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

8.  Differentiation of chronic mass-forming pancreatitis from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.

Authors:  Shuai Ren; Xiao Chen; Wenjing Cui; Rong Chen; Kai Guo; Huifeng Zhang; Shuai Chen; Zhongqiu Wang
Journal:  Cancer Manag Res       Date:  2019-08-20       Impact factor: 3.989

Review 9.  Abdominal manifestations of IgG4-related disease: a pictorial review.

Authors:  Christopher Siew Wai Tang; Nishanth Sivarasan; Nyree Griffin
Journal:  Insights Imaging       Date:  2018-04-25

10.  Pancreas Ductal Adenocarcinoma and its Mimics: Review of Cross-sectional Imaging Findings for Differential Diagnosis.

Authors:  Seung Soo Kim; Gyo Chang Choi; Sung Shick Jou
Journal:  J Belg Soc Radiol       Date:  2018-10-26       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.